Pulse Biosciences Inc. (NASDAQ:PLSE) stock is trading higher on continued strength after the company on Friday shared clinical data from its nPulse Cardiac Catheter first-in-human feasibility study.
The surge comes as the stock gains momentum, while the broader market experienced slight declines, with the Nasdaq down 0.14% and the S&P 500 down 0.05%, indicating that the stock’s movement is largely driven by company-specific news rather than overall market trends.
nPulse Cardiac Catheter Shows Promising Results
Pulse Biosciences unveiled significant clinical data from its nPulse Cardiac Catheter first-in-human feasibility study on February 6.
The study highlighted successful treatment outcomes for atrial fibrillation in 150 patients, showcasing rapid procedure times and minimal adverse effects, which could position the nPulse technology as a leading option in the market.
The findings were presented at the Annual AF Symposium 2026 in Boston, emphasizing the potential of the nPulse Cardiac Catheter to advance treatment for atrial fibrillation. The company is preparing to treat additional patients as it initiates a pivotal IDE study.
PLSE Stock Surges Above Moving Averages
The stock is currently trading 49% above its 20-day simple moving average (SMA) and 39.4% above its 100-day SMA, indicating strong short-term momentum. Over the past 12 months, shares have decreased by 7.20%, and they are currently positioned closer to their 52-week highs than lows, suggesting a recovery phase.
The RSI is at 75.62, indicating that the stock is in overbought territory, while the MACD is above its signal line, reflecting bullish momentum. The combination of an overbought RSI and bullish MACD suggests mixed momentum, indicating that while the stock is performing well, caution may be warranted due to potential overextension.
- Key Resistance: $24.50
- Key Support: $20.00
Benzinga Edge Ranks PLSE Strong in Momentum
Below is the Benzinga Edge scorecard for Pulse Biosciences stock, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Strong (Score: 68.22) — Stock is outperforming the broader market.
The Verdict: Pulse Biosciences’ stock’s Benzinga Edge signal reveals a strong momentum score, indicating that the stock is currently performing well relative to the market. However, investors should remain cautious given the overbought RSI condition and monitor for any signs of reversal.
PLSE Price Action: Pulse Biosciences shares were up 4.05% at $21.59 during premarket trading on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments